{"links":{"feed":"https://www.erudio.com/reports/suprame-nct06743126/feed.json","html":"https://www.erudio.com/reports/suprame-nct06743126","json":"https://www.erudio.com/reports/suprame-nct06743126.json","markdown":"https://www.erudio.com/reports/suprame-nct06743126.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"suprame-nct06743126"}},"request":"https://www.erudio.com/contact?report=suprame-nct06743126"},"offer":{"cited_clinicians":9,"cited_commentary_sources":39,"verified_hcp_statements":108,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":10},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"suprame-nct06743126"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=suprame-nct06743126","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/suprame-nct06743126","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 108 verified statements · 56 from 9 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T05:52:02.370292Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":7,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":7,"title":"Primary endpoint: Progression-free survival assessed by BICR"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":17,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":11,"title":"Population and setting"},{"claim_count":21,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":11,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":18,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":14,"title":"Design and conduct"},{"claim_count":11,"coverage":"discussed","id":"A1","source_count":7,"title":"HLA and PRAME work-up"},{"claim_count":12,"coverage":"discussed","id":"A2","source_count":8,"title":"Sequencing, progression monitoring and trial referral"},{"claim_count":13,"coverage":"discussed","id":"A3","source_count":8,"title":"Manufacturing, administration and service readiness"},{"claim_count":18,"coverage":"discussed","id":"A4","source_count":17,"title":"Earlier IMA203 phase 1/1b evidence and its relevance to SUPRAME expectations"},{"claim_count":16,"coverage":"discussed","id":"A5","source_count":12,"title":"Secondary-source forecasts and competing-development benchmarks"},{"claim_count":6,"coverage":"discussed","id":"A6","source_count":5,"title":"Potential PRAME platform beyond melanoma"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":5,"cited_clinicians":9,"cited_clinicians_by_role":{"physician":4,"physician, Hematology and oncology":1,"physician, Medical oncology":4},"cited_physicians":9,"cited_sources":39,"claims_by_expression_type":{"comparison":21,"experience":4,"interpretation":26,"opinion":28,"question":3,"restatement":18,"uncertainty":5,"unspecified":3},"claims_by_kind":{"source_observation":108},"clinician_statements":56,"evidence_units":69,"findings":10,"organisational_accounts":9,"people_cited":16,"people_identity_verified":10,"people_total":16,"screened_sources":66,"verified_claims":108},"findings_index":[{"cited_clinicians":5,"id":"F1","structure":{"claims":25,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":6,"views":16},"limitations":3,"links":{"context":2,"support":25},"ma_question":true,"named_voices":8,"passages":20,"sources":18,"sources_by_kind":{"commentary":12,"media":6}},"title":"Phase 1 IMA203: what most speakers highlight in PD-1-refractory melanoma response rates","title_holders":{"cited_claim_ids":["claim-52ab7acee85d91999335","claim-145c6667805cbefe2aec","claim-ad5f5d71251a2a0ba56d","claim-6c9a3b199fb295084fac","claim-a5f963cf63f76dd3d5ee","claim-6ce789b12d6faa0d98c8","claim-d7b234d796c8c068c1fd","claim-84b6d501ff06e9bfe177","claim-5427c0532207928c6137","claim-923dbc02e05351526aa9","claim-7d58bc18f8fd352b6d20","claim-12bf628cc92954113cdf","claim-431079bb61745f848a86","claim-e1b4dcaedef3070baf5b","claim-3f305e4de4bf56f6f8d9"],"clinicians":false,"holders":7,"speakers":8,"view":"reading"},"evidence_line":"25 statements from 8 speakers in 18 sources, 6 of them podcasts or videos","holder_line":"7 of the 8 named speakers in this finding hold this view"},{"cited_clinicians":2,"id":"F2","structure":{"claims":17,"claims_by_group":{"comparisons":13,"experience":0,"questions":2,"restated":1,"views":1},"limitations":2,"links":{"context":1,"support":17},"ma_question":true,"named_voices":4,"passages":11,"sources":8,"sources_by_kind":{"commentary":3,"media":5}},"title":"IMA203 vs TIL: some clinicians value no surgery; one flags therapy intensity","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-194611a7a30e08a05c1f"],"clause":"one flags therapy intensity","holders":1},"cited_claim_ids":["claim-22ff9a1c1c7582ba6b3c","claim-7ecb5cb77491956bb952","claim-a26462047ee1eb1f4f56","claim-cc3e9cdfd06713bb3f12","claim-a36554e1ad2fe2b02811","claim-72a491f7b3a4d4aa0719"],"clinicians":true,"holders":2,"speakers":4,"view":"reading"},"evidence_line":"17 statements from 4 speakers in 8 sources, 5 of them podcasts or videos","holder_line":"2 of the 4 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags therapy intensity”"},{"cited_clinicians":2,"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":4,"experience":1,"questions":0,"restated":4,"views":1},"limitations":4,"links":{"context":2,"support":10},"ma_question":true,"named_voices":4,"passages":9,"sources":8,"sources_by_kind":{"commentary":3,"media":5}},"title":"Phase 1 IMA203 safety: where speakers split on the toxicity burden","title_holders":{"cited_claim_ids":["claim-af915c464184a145de3a","claim-7dfe441149d44a9d90a5","claim-d7b234d796c8c068c1fd","claim-6124d62b3761ba5f51e1","claim-923dbc02e05351526aa9","claim-8a04a9ac0d7489bded4f","claim-45e31e5907fe621c703f","claim-22ff9a1c1c7582ba6b3c","claim-194611a7a30e08a05c1f"],"clinicians":false,"holders":4,"speakers":4,"view":"split"},"evidence_line":"10 statements from 4 speakers in 8 sources, 5 of them podcasts or videos","holder_line":"4 of the 4 named speakers in this finding take a side on this question"},{"cited_clinicians":3,"id":"F4","structure":{"claims":13,"claims_by_group":{"comparisons":3,"experience":0,"questions":2,"restated":2,"views":6},"limitations":3,"links":{"context":2,"support":13},"ma_question":true,"named_voices":5,"passages":12,"sources":9,"sources_by_kind":{"commentary":4,"media":5}},"title":"IMA203 access: why most speakers stress HLA matching","title_holders":{"cited_claim_ids":["claim-541fc5dc39492f1dc1fd","claim-807b37a6a867a0e4bd7f","claim-ea9626c55dbaf599bae5","claim-e89e7fdfbc878d4de49a","claim-fada40f89856f29c47aa","claim-ff328c519892b394d500","claim-58dba4b72e4175d77141"],"clinicians":false,"holders":3,"speakers":5,"view":"reading"},"evidence_line":"13 statements from 5 speakers in 9 sources, 5 of them podcasts or videos","holder_line":"3 of the 5 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F5","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":0,"views":3},"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"media":2}},"title":"Cell therapy: what speakers say","evidence_line":"5 statements from 1 speaker in 2 sources, all podcasts or videos"},{"cited_clinicians":3,"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":6,"views":6},"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":3,"passages":9,"sources":7,"sources_by_kind":{"commentary":1,"media":6}},"title":"SUPRAME: why clinicians value randomization; one frames it as TCR vs TIL","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-30b46f0baebe941a3167"],"clause":"one frames it as TCR vs TIL","holders":1},"cited_claim_ids":["claim-d55c0da740254bb9312b","claim-8576218dee2e7f2d017b","claim-3fcf7c1c9432ad656923","claim-30b46f0baebe941a3167","claim-b931501c5f6c556350c1"],"clinicians":true,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"12 statements from 3 speakers in 7 sources, 6 of them podcasts or videos","holder_line":"3 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one frames it as TCR vs TIL”"},{"cited_clinicians":4,"id":"F7","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":1,"views":11},"limitations":2,"links":{"context":0,"support":14},"ma_question":true,"named_voices":5,"passages":14,"sources":14,"sources_by_kind":{"commentary":11,"media":3}},"title":"Cell therapy: what speakers say","evidence_line":"14 statements from 5 speakers in 14 sources, 3 of them podcasts or videos"},{"cited_clinicians":0,"id":"F8","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":4,"views":4},"limitations":3,"links":{"context":2,"support":16},"ma_question":true,"named_voices":2,"passages":9,"sources":7,"sources_by_kind":{"commentary":7}},"title":"SUPRAME: what speakers say","evidence_line":"12 statements from 2 speakers in 7 sources"},{"cited_clinicians":0,"id":"F9","structure":{"claims":10,"claims_by_group":{"comparisons":4,"experience":0,"questions":1,"restated":0,"views":5},"limitations":4,"links":{"context":8,"support":16},"ma_question":true,"named_voices":0,"passages":8,"sources":7,"sources_by_kind":{"commentary":7}},"title":"SUPRAME: what speakers say","evidence_line":"10 statements in 7 sources"},{"cited_clinicians":4,"id":"F10","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":0,"views":5},"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"PRAME-directed TCR-T: some clinicians consider broader solid-tumor use possible","title_holders":{"cited_claim_ids":["claim-b762ac63c6a51452e286","claim-39145fa3f4dcd6f6385e","claim-4799303bd72ea8fc3159"],"clinicians":true,"holders":2,"speakers":4,"view":"reading"},"evidence_line":"7 statements from 4 speakers in 5 sources, 3 of them podcasts or videos","holder_line":"2 of the 4 named speakers in this finding hold this view, each a confirmed clinician"}],"open_question":{"basis":"From findings F1 (25 statements from 8 speakers in 18 sources) and F6 (12 statements from 3 speakers in 7 sources)","cited_claim_ids":["claim-145c6667805cbefe2aec","claim-53c9928d561e619881b1","claim-399caf84de5bfb4514fb","claim-3fcf7c1c9432ad656923","claim-12bf628cc92954113cdf","claim-6988fef840fda34e3177","claim-7cde955ebe050b280290","claim-8576218dee2e7f2d017b","claim-62bdabf127b37f947dde","claim-bc78cf776656e4db4c6e","claim-afb8ef213f9b6be382a4","claim-30b46f0baebe941a3167","claim-b931501c5f6c556350c1"],"finding_ids":["F1","F6"],"question":"What do clinicians need SUPRAME to show on progression-free survival versus investigator's choice before using IMA203 as standard care for HLA-A*02:01-positive, PD-1-refractory unresectable or metastatic cutaneous melanoma?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers see substantial post-PD-1 promise in earlier IMA203 studies"},{"id":"section-2","level":2,"title":"Speakers favor the procedural comparison with TIL, while one stresses treatment intensity"},{"id":"section-3","level":2,"title":"An X summary reports severe CRS; an episode raises later-line toxicity concerns"},{"id":"section-4","level":2,"title":"Speakers emphasize HLA restriction and testing before considering access"},{"id":"section-5","level":2,"title":"One episode advocates earlier cell therapy after clear checkpoint failure, not automatic frontline replacement"},{"id":"section-6","level":2,"title":"Speakers value the randomized comparison; one frames it as TCR therapy versus TIL therapy"},{"id":"section-7","level":2,"title":"Speakers encourage trial awareness, while one episode anticipates a major delivery shift"},{"id":"section-8","level":2,"title":"X accounts differ over the meaning of protocol changes and the expected readout timing"},{"id":"section-9","level":2,"title":"Relayed analyst notes project success but attach survival, safety and execution conditions"},{"id":"section-10","level":2,"title":"Beyond the trial population"},{"id":"section-11","level":3,"title":"Speakers see PRAME-directed therapy as a possible broader solid-tumor platform"},{"id":"section-12","level":2,"title":"Scope and coverage of the sources reviewed"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F6","shared_claims":2},{"id":"F8","shared_claims":5}],"id":"T1","label":"Primary endpoint: Progression-free survival assessed by BICR"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F9","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":10},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":3},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":14},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":3},{"id":"F9","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":8},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":7},{"id":"F7","shared_claims":2},{"id":"F8","shared_claims":9}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T05:52:02.370292Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T06:07:24Z","record_hash":"52b1ef7aed38ab51321e905d399cb1a5528b9fd9604875e1be51ca8d1e29ece0","release_hash":"0a3613f9041f18b70fb00c03d7a922311a03ea6e570acd12d1897c4fae73659e","report_id":"erudio-nct06743126","run_id":"5b342c07-6fc9-4f1e-b84b-5c3012b98223","schema_version":"5.0","slug":"suprame-nct06743126","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"For SUPRAME, the clinicians cited see potential to change care based on earlier response activity, but comparative benefit remains unproven. One physician sees a possible option for some patients unsuitable for lifileucel, dependent on HLA matching and future approval. A physician described in the sources as presenting the trial cautions that treatment remains intensive despite avoiding surgery. Comparative safety remains uncertain, and differing descriptions of interleukin support remain unresolved.","examples":[{"claim_id":"claim-72e8c0d822944c907204","finding_id":"F1","identity_check":"npi_registry","month":"2026-01","region":"US","role":"Physician","source_type":"podcast","statement":"identifies the SUPRAME trial as one of the trials generating the most excitement."}],"meta_description":"66 sources screened · 108 verified statements (56 from clinicians verified by NPI or staff page) from 39 sources · 10 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T06:07:24Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-20T06:07:24Z","kind":"routine","summary":"The trial's name is spelled as its investigators write it, “SUPRAME” (NCT06743126), outside quotations (was “SURPRAME”)."},{"affected_ids":[],"date":"2026-11-20T06:07:24Z","kind":"routine","summary":"An editorial bracket follows a transcription-garbled trial name in quotations: “SURPRAME [SUPRAME]”."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":66},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on enthusiasm for the investigational cell therapy and enrollment in its phase three trial; a remark on the treatment comparison in previously treated unresectable or metastatic cutaneous melanoma; a view on anticipated local trial access as another treatment option for advanced melanoma; a view on earlier tolerability evidence for investigational T-cell therapy in previously treated advanced melanoma.","2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.","3 passages in 3 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","37 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 9 sources about other trials or topics are not included.","The sources reviewed for this edition are a selected public discussion, not a representative HCP survey. Repeated statements and cross-platform posts cannot be counted as independent clinician agreement.","Discussion without recognized trial or drug wording may be absent. Several possible passages were not fully assessed, and some earlier discussion and media relays are not represented; additional or historically earlier views may therefore be missing.","Coverage of alternative investigational choices and account-level preferences is incomplete. The HLA-typing point and uveal-enrollment question alone do not describe those choices or preferences.","No full SUPRAME protocol or exact-trial publication was available in the reviewed material to reconcile secondary amendment descriptions. Exact regulatory labeling for IMA203 and nivolumab plus relatlimab was also incomplete, limiting independent confirmation of authorized-use descriptions.","The cited efficacy and safety observations concern earlier IMA203 studies, not randomized SUPRAME outcomes. Accounts describing a cutaneous-melanoma cohort, heavily refractory advanced melanoma or metastatic melanoma should not be pooled as if they described one population.","Earlier accounts give different prior-treatment figures, response wording and IL-2 descriptions. Those differences remain unresolved rather than being silently harmonized, and the episode's unattributed IL-2 wording does not establish disagreement between named speakers.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Relayed company announcements, analyst notes and a research note's interpretation of a KOL survey are not direct individual HCP testimony. Probabilities, comparative labels and survival benchmarks remain those sources' assessments.","Activation accounts, eligibility descriptions and projected readout or filing dates retain their original timing. They do not establish present site availability, a current complete eligibility checklist or completed regulatory milestones."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":5,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":24,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":39},"count":39,"evidence_window":{"end":"2026-10-30","start":"2024-10-11"},"retrieval_snapshot":"2026-11-20T03:29:00.767230Z","timeline":[{"count":1,"week":"2024-W41"},{"count":2,"week":"2024-W45"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W03"},{"count":5,"week":"2025-W11"},{"count":1,"week":"2025-W15"},{"count":3,"week":"2025-W16"},{"count":2,"week":"2025-W22"},{"count":1,"week":"2025-W27"},{"count":1,"week":"2025-W29"},{"count":2,"week":"2025-W30"},{"count":1,"week":"2025-W34"},{"count":2,"week":"2025-W35"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W27"},{"count":2,"week":"2026-W34"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":2,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06743126:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06743126:context","quote_policy":"short_quote_link_out"},{"id":"openfda:4121bd3f-2d6e-3bdd-e063-6294a90a3088:20251014","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2kc5txp5ecqq4k2ff5kog4vw-3lk7vaqis6c2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2kc5txp5ecqq4k2ff5kog4vw-3lmrfplyw722o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-57rttgtm5rorqeezlptidrco-3mbtw3sded22c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3ltjrrxeqk22j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-fptm2gxhu5ik4zs4apgth6kv-3lxauohxggs2l","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-l55dzcmlyyo4eepx44w7pydk-3lkb7r2kfns2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qyujkew4stld75zfscfvpaqu-3lkba2hdnhs2v","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7260404327305900032","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7305754947495624704","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7317501219327926273","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7353028438569426945","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7467320357532770304","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3dd553","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5b937f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:cec825","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844324576517554689:fe66e0e0-f3b0-41d2-9fec-6166a0a4ae5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844325000725291192:3cd44b8f-d1f7-4870-bec7-7f824e02aeda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844325010376101981:99ee7fd1-d016-4582-a1f4-ecf54361bad6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844329092205936817:6dcca833-8b8b-4a67-8366-14efbf05cd42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844329140784353393:1f4c53f0-e36b-44b8-b7be-22598ecd6114","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844330358176874957:f41144bf-884c-4b0e-b2ee-c6d198ce131d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844339556952518850:3ab246a2-7b16-4f92-a675-e3aba81d689c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844398850804715745:3db6e6fa-253d-48ad-836e-1fb7c2754b4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844425630047183080:b2678894-31b6-4d33-927c-9dca62f6360d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844720187242651735:cc3d2315-1d0a-415b-b68f-217378839396","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1854635825486872944:290410d0-b703-490b-ac23-daa6156fd6df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1877036582567645317:015363f7-e888-4a16-9719-cde99ed2668d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879617023346683924:8d998f54-8710-4295-b8a2-9f588d6a079e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1899987745248075915:744eb137-44f9-46ac-b40f-2f79ae332a97","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1909930674888278418:462d028c-c66b-477a-b3b4-db30da74089b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1911735488496402613:feba70d8-a9ae-4de6-b961-c17abd6d30b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1924089672315130007:7b5162b9-0d84-451b-8f37-9b89bc46b31d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1927706290337267795:2e6f6247-ff4c-4333-bb17-8ec447dde39f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929276642326630510:afc372bf-d933-4558-ae85-45608fc12b9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929650325587099988:85d3a501-a394-4250-893c-ec885d2dc92b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930121222823784675:5f93e647-a105-4291-900c-8721cd84e793","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938878404964544702:00b6f81e-939e-4d6d-9f0e-4310768b95e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940561130231078957:974fb782-f8c9-4f63-8008-1f09b68c4036","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940923512505442460:65e87cc4-2705-4534-b0f4-2c63091c4bb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1942918606632677469:cc258b90-9619-40eb-aaf7-d119d1457867","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1943519758290423815:2caf88ab-c74d-4ac2-8f01-1617e47232d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1947267418344054828:2eaae4b3-6ac9-4478-a137-d7a6def0eae9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1948488355051688234:7122c041-1b6a-48de-8512-ca77b9809ea5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1951160967858979136:0bc5d03b-6fbe-41a2-8397-e8a909c52543","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1952021634820227088:a51b162f-1a05-4d1a-8df8-18f2d9ecad12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957533221647683593:181ee309-14fc-436d-b708-eb5b9984516b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1988017779803328990:e54fd02d-1b71-4edb-b0bf-900c59e7939a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1990464262003712479:677741a9-8fb6-48f3-a657-1c7d6f3a2bf7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1996972164738691486:d8bae617-1bac-4e8c-ac36-57a716e7a57d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2008598371406434676:961467fa-bbb3-4769-af8f-40e05c62cf77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060858907594043755:5431fd62-c0f8-482b-b977-cb33f81ea71b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061527295236481093:d505bc56-35af-4f8b-b944-1c2b904a7c43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066794301137256629:0596407b-c10d-4fe2-903c-903ea3a035d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2071765495510970730:766143ff-590e-4626-a16f-c9a55cfc1fa0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089675451459305653:a64c08f8-6070-45ae-8667-49bdad2f16ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089682285968969861:d9dd3d4f-6745-49e2-b52a-4a294dab3b34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090108308858470767:2f39b63a-59e9-4767-b4ad-04bf37938f34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105276249241420035:135f2b77-f1fb-40de-9a27-0fd3d6e83416","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107537957590802754:b330dcb1-0b29-4ea1-82ec-2d0c9c83523f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111958339454140746:1853dd84-231b-4e84-b348-248f9addeb6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114736303413895473:157f36ff-0639-4949-91be-48294bf11825","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116198984176075168:4aa608af-59df-43e7-a597-9517563390a0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:2Bucyq39w-o","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:HH9I1BAbDRs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:LDsYYQdQcUs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:olhwqbRtFZs","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":7,"linkedin_post":5,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":47,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":66},"count":66,"evidence_window":{"end":"2026-10-30","start":"2024-10-10"},"retrieval_snapshot":"2026-11-20T03:29:00.767230Z","timeline":[{"count":10,"week":"2024-W41"},{"count":2,"week":"2024-W45"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W03"},{"count":5,"week":"2025-W11"},{"count":1,"week":"2025-W15"},{"count":3,"week":"2025-W16"},{"count":1,"week":"2025-W20"},{"count":2,"week":"2025-W22"},{"count":3,"week":"2025-W23"},{"count":1,"week":"2025-W26"},{"count":3,"week":"2025-W27"},{"count":3,"week":"2025-W28"},{"count":1,"week":"2025-W29"},{"count":3,"week":"2025-W30"},{"count":2,"week":"2025-W31"},{"count":1,"week":"2025-W34"},{"count":3,"week":"2025-W35"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W49"},{"count":2,"week":"2026-W02"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W27"},{"count":3,"week":"2026-W34"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":2,"week":"2026-W44"}],"undated_sources":1},"statements_by_channel":{"bluesky_thread":4,"linkedin_post":5,"other":0,"podcast":31,"publication":0,"registry":0,"regulatory":0,"x_thread":46,"x_video":0,"youtube":22}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"anzutresgene autoleucel","slug":"anzutresgene-autoleucel"},{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"relatlimab","slug":"relatlimab"},{"brand_names":["Amtagvi"],"label":"lifileucel","slug":"lifileucel"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Yervoy"],"label":"ipilimumab","slug":"ipilimumab"},{"brand_names":["Dtic-Dome"],"label":"dacarbazine","slug":"dacarbazine"},{"brand_names":["Temodar"],"label":"temozolomide","slug":"temozolomide"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Abraxane"],"label":"nab-paclitaxel","slug":"nab-paclitaxel"}],"indications":[{"reason":"Unmapped registry condition: Melanoma, Cutaneous Malignant","status":"unmapped"},{"reason":"Unmapped registry condition: Mucosal Melanoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Melanoma","slug":"melanoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"SUPRAME","aliases":["SUPRAME","SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)"],"brief_title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Melanoma, Cutaneous Malignant","Mucosal Melanoma"],"display_condition":"previously treated, unresectable or metastatic cutaneous melanoma","display_interventions":[["anzutresgene autoleucel (IMA203)"]],"enrollment":{"count":450,"type":"ESTIMATED"},"interventions":[{"name":"IMA203","synonyms":["anzutresgene autoleucel","anzu-cel"],"type":"BIOLOGICAL"},{"name":"nivolumab plus relatlimab","synonyms":["Opdualag®"],"type":"BIOLOGICAL"},{"name":"lifileucel","synonyms":["AMTAGVI"],"type":"BIOLOGICAL"},{"name":"nivolumab","synonyms":["Opdivo®"],"type":"BIOLOGICAL"},{"name":"pembrolizumab","synonyms":["Keytruda®"],"type":"BIOLOGICAL"},{"name":"ipilimumab","synonyms":["Yervoy"],"type":"BIOLOGICAL"},{"name":"Dacarbazine","synonyms":["DTIC-Dome"],"type":"DRUG"},{"name":"temozolomide","synonyms":["Temodar"],"type":"DRUG"},{"name":"paclitaxel","synonyms":["Taxol"],"type":"DRUG"},{"name":"paclitaxel plus carboplatin","synonyms":["Carbo/Taxol®"],"type":"DRUG"},{"name":"Albumin-Bound Paclitaxel","synonyms":["Abraxane®"],"type":"DRUG"}],"nct_id":"NCT06743126","official_title":"A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"progression-free survival (PFS), centrally assessed (by blinded independent central review) using RECIST 1.1","measure":"Progression-free survival assessed by BICR","timeFrame":"up to 5 years post first treatment of last patient"}],"registered_date":{"date":"2024-12-19","type":"ACTUAL"},"registry_last_updated":"2026-10-30","registry_url":"https://clinicaltrials.gov/study/NCT06743126","short_name":"SUPRAME","short_name_basis":"registry_acronym","sponsor":"Immatics US, Inc.","start_date":{"date":"2025-01-14","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"IMA203-301","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}